MilliporeSigma receives the industry

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

$FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma$

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

Kimera® Labs named a semifinalist in the $101 million XPRIZE Healthspan competition for pioneering innovations in healthy aging

Kimera® Labs named a semifinalist in the $101 million XPRIZE Healthspan competition for pioneering innovations in healthy aging

By Kimera
Kimera
12 May 2025

Rein Therapeutics announces the initiation of the RENEW Phase 2 trial of LTI-03 in patients with IPF

Rein Therapeutics announces the initiation of the RENEW Phase 2 trial of LTI-03 in patients with IPF

By Rein Therapeutics, Inc.
Rein Therapeutics, Inc.
12 May 2025

Viralgen Partners with Trogenix to Advance AAV Gene Therapy for Glioblastoma

Viralgen Partners with Trogenix to Advance AAV Gene Therapy for Glioblastoma

By Viralgen
Viralgen
07 May 2025

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

By Niagen Bioscience, Inc
Niagen Bioscience, Inc
06 May 2025

INBRAIN Neuroelectronics has been awarded a €4 million grant from Spain’s PERTE Chip Program to advance graphene-based brain-computer interfaces

INBRAIN Neuroelectronics has been awarded a €4 million grant from Spain’s PERTE Chip Program to advance graphene-based brain-computer interfaces

By INBRAIN Neuroelectronics
INBRAIN Neuroelectronics
06 May 2025

At DDW’25, NImmune Biopharma will present the first-ever head-to-head clinical and translational results for Omilancor versus the leading anti-TL1A in IBD, demonstrating superiority and complementarity

At DDW’25, NImmune Biopharma will present the first-ever head-to-head clinical and translational results for Omilancor versus the leading anti-TL1A in IBD, demonstrating superiority and complementarity

By NImmune Biopharma
NImmune Biopharma
06 May 2025

Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular

Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

By Innorna Co. Ltd.

Apr 28
Stay Protected

By Family Features Editorial Syndicate

Aug 09
Avenacy Enters U.S. Market with Launch of Doxycycline for Injection, USP

By Avenacy

May 27

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

User Area

Discover

Engage with Us